Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

In 2013, itolizumab received approval in India as a safe and effective treatment for plaque psoriasis. In aGVHD, steroid-insensitive CD6-high T cells contribute to gastrointestinal inflammation ...

Per the study protocol, patients received itolizumab within 3-days of the first administration of high-dose corticosteroids with a treatment period from Days 1-99, and a follow-up period from Days 100 ...

Equillium Inc. is forging ahead with regulatory plans for itolizumab in first-line treatment of patients with acute graft-vs.-host disease (GVHD), despite a phase III disappointment. Shares of the La ...

Itolizumab demonstrated clinical efficacy after ... experts in the field of inflammatory bowel disease (IBD). "The CD6-ALCAM pathway is elevated in gastrointestinal inflammation and is associated ...

Equillium (NASDAQ:EQ – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on ...

Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T ...